Dalpiciclib (SHR-6390)
Jump to navigation
Jump to search
Mechanism of action
From NCI Drug Dictionary: A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation.
Preliminary data
Breast cancer
- DAWNA-1: NCT03927456
Also known as
- Code name: SHR6390